Raghavan Rajagopalan
Raghavan Rajagopalan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Carla Ghelardini
Department of Neuroscience, Psychology, Drug Research and Child Health—NEUROFARBA—Pharmacology and Toxicology Section University of Florence Florence Italy
2 shared publications Parthasarathi Rajagopalan
Daya Drug Discoveries, Inc., 204 City Gate Lane, St. Louis, MO 63146, USA
2 shared publicationsAcintya Bandyopadhyaya
Daya Drug Discoveries, Inc., University of Missouri, St. Louis, One University Blvd., St. Louis, MO 63121, USA
1 shared publication- Alessandra Pacini
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
1 shared publication Amruta R Poreddy
Covidien
1 shared publicationBethel Asmelash
Covidien
1 shared publication
Latest Publications
- 9 September 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 95, 129472
DDD-028: A potent, neuroprotective, non-opioid compound for the treatment of diabetic neuropathy
- 9 September 2023
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 95, 129472
DDD-028: A potent, neuroprotective, non-opioid compound for the treatment of diabetic neuropathy
- Open Access
- 7 August 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2581-2595
Broad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy
Neurotoxicity of chemotherapeutics involves peculiar alterations in the structure and function, including abnormal nerve signal transmission, of both the peripheral and central nervous system. The lack of effective pharmacological approaches to prevent chemotherapy-induced neurotoxicity necessitates the identification of innovative therapies. Recent evidence suggests that repeated treatment with the pentacyclic pyridoindole derivative DDD-028 can exert both pain-relieving and glial modulatory effects in mice with paclitaxel-induced neuropathy. This work is aimed at assessing whether DDD-028 is a disease-modifying agent by protecting the peripheral nervous tissues from chemotherapy-induced damage. Neuropathy was induced in animals by paclitaxel injection (2.0 mg kg −1 i.p). DDD-028 (10 mg kg −1 ) and the reference drug, pregabalin (30 mg kg −1 ), were administered per os daily starting concomitantly with the first injection of paclitaxel and continuing 10 days after the end of paclitaxel treatment. The behavioural tests confirmed the antihyperalgesic efficacy of DDD-028 on paclitaxel-induced neuropathic pain. Furthermore, the electrophysiological analysis revealed the capacity of DDD-028 to restore near-normal sensory nerve conduction in paclitaxel-treated animals. Histopathology evidence indicated that DDD-028 was able to counteract effectively paclitaxel-induced peripheral neurotoxicity by protecting against the loss of intraepidermal nerve fibers, restoring physiological levels of neurofilament in nerve tissue and plasma, and preventing morphological alterations occurring in the sciatic nerves and dorsal root ganglia. Overall, DDD-028 is more effective than pregabalin in preventing chemotherapy-induced neurotoxicity. Thus, based on its potent antihyperalgesic and neuroprotective efficacy, DDD-028 seems to be a viable prophylactic medication to limit the development of neuropathies consequent to chemotherapy.
- 7 August 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2581-2595
Open AccessBroad-spectrum neuroprotection exerted by DDD-028 in a mouse model of chemotherapy-induced neuropathy
Neurotoxicity of chemotherapeutics involves peculiar alterations in the structure and function, including abnormal nerve signal transmission, of both the peripheral and central nervous system. The lack of effective pharmacological approaches to prevent chemotherapy-induced neurotoxicity necessitates the identification of innovative therapies. Recent evidence suggests that repeated treatment with the pentacyclic pyridoindole derivative DDD-028 can exert both pain-relieving and glial modulatory effects in mice with paclitaxel-induced neuropathy. This work is aimed at assessing whether DDD-028 is a disease-modifying agent by protecting the peripheral nervous tissues from chemotherapy-induced damage. Neuropathy was induced in animals by paclitaxel injection (2.0 mg kg −1 i.p). DDD-028 (10 mg kg −1 ) and the reference drug, pregabalin (30 mg kg −1 ), were administered per os daily starting concomitantly with the first injection of paclitaxel and continuing 10 days after the end of paclitaxel treatment. The behavioural tests confirmed the antihyperalgesic efficacy of DDD-028 on paclitaxel-induced neuropathic pain. Furthermore, the electrophysiological analysis revealed the capacity of DDD-028 to restore near-normal sensory nerve conduction in paclitaxel-treated animals. Histopathology evidence indicated that DDD-028 was able to counteract effectively paclitaxel-induced peripheral neurotoxicity by protecting against the loss of intraepidermal nerve fibers, restoring physiological levels of neurofilament in nerve tissue and plasma, and preventing morphological alterations occurring in the sciatic nerves and dorsal root ganglia. Overall, DDD-028 is more effective than pregabalin in preventing chemotherapy-induced neurotoxicity. Thus, based on its potent antihyperalgesic and neuroprotective efficacy, DDD-028 seems to be a viable prophylactic medication to limit the development of neuropathies consequent to chemotherapy.
- 1 July 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (14) , 3088-3091
DDD-028: A potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain
- 1 July 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (14) , 3088-3091
DDD-028: A potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain
- 7 February 2008
- Published by SPIE-Intl Soc Optical Eng
- Vol. 6867, 68670C-68670C-11
New optical probes for the continuous monitoring of renal function
The ability to continuously monitor renal function via the glomerular filtration rate (GFR) in the clinic is currently an unmet medical need. To address this need we have developed a new series of hydrophilic fluorescent probes designed to clear via glomerular filtration for use as real time optical monitoring agents at the bedside. The ideal molecule should be freely filtered via the glomerular filtration barrier and be neither reabsorbed nor secreted by the renal tubule. In addition, we have hypothesized that a low volume of distribution into the interstitial space could also be advantageous. Our primary molecular design strategy employs a very small pyrazine-based fluorophore as the core unit. Modular chemistry for functionalizing these systems for optimal pharmacokinetics (PK) and photophysical properties have been developed. Structure-activity relationship (SAR) and pharmacokinetic (PK) studies involving hydrophilic pyrazine analogues incorporating polyethylene glycol (PEG), carbohydrate, amino acid and peptide functionality have been a focus of this work. Secondary design strategies for minimizing distribution into the interstitium while maintaining glomerular filtration include enhancing molecular volume through PEG substitution. In vivo optical monitoring experiments with advanced candidates have been correlated with plasma PK for measurement of clearance and hence GFR.
- 7 February 2008
- Published by SPIE-Intl Soc Optical Eng
- Vol. 6867, 68670C-68670C-11
New optical probes for the continuous monitoring of renal function
The ability to continuously monitor renal function via the glomerular filtration rate (GFR) in the clinic is currently an unmet medical need. To address this need we have developed a new series of hydrophilic fluorescent probes designed to clear via glomerular filtration for use as real time optical monitoring agents at the bedside. The ideal molecule should be freely filtered via the glomerular filtration barrier and be neither reabsorbed nor secreted by the renal tubule. In addition, we have hypothesized that a low volume of distribution into the interstitial space could also be advantageous. Our primary molecular design strategy employs a very small pyrazine-based fluorophore as the core unit. Modular chemistry for functionalizing these systems for optimal pharmacokinetics (PK) and photophysical properties have been developed. Structure-activity relationship (SAR) and pharmacokinetic (PK) studies involving hydrophilic pyrazine analogues incorporating polyethylene glycol (PEG), carbohydrate, amino acid and peptide functionality have been a focus of this work. Secondary design strategies for minimizing distribution into the interstitium while maintaining glomerular filtration include enhancing molecular volume through PEG substitution. In vivo optical monitoring experiments with advanced candidates have been correlated with plasma PK for measurement of clearance and hence GFR.